drugset / Trial / NCT06738745

Study of HRS-2189 Combined HRS-5041 in Prostate Cancer

NCT06738745

Phase 2 Not yet recruiting 90 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

Our study is aimed to evaluate the efficacy and safety of HRS-2189 combined with HRS-5041 in metastatic prostate cancer.

Timeline

Start
2024-12-31
Primary completion
2027-01-31
Completion
2027-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-2189 Unknown
Subject HRS-5041 Other / unclassified